Physician profile
Mark Stellingworth
NPI 1003000936
$2,422.55
in general payments reported to CMS, 2019-2025
18 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $127 · 2021: $298 · 2022: $675 · 2023: $589 · 2024: $450 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,303.14 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $455.71 | 2020-2025 | |
| Amgen INC. | $352.88 | 2020-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $304.09 | 2022-2025 | Verquvo |
| Abbott Laboratories | $280.38 | 2021-2024 | Mitraclip, Cardiomems, Jot Dx |
| Philips North America LLC | $182.73 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, Event, Extended Holter |
| E.R. Squibb & Sons, L.L.C. | $137.39 | 2020-2024 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $108.22 | 2021-2023 | Xarelto |
| Pfizer INC. | $106.16 | 2020-2022 | |
| Esperion Therapeutics, INC. | $82.56 | 2024-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $80.46 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $77.66 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.99 | 2022-2025 | Lifevest |
| Amarin Pharma, INC. | $52.20 | 2021 | |
| Alnylam Pharmaceuticals INC. | $51.61 | 2022-2025 | Onpattro |
| Cvrx, INC. | $33.50 | 2022-2023 | Barostim Neo System |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $20.18 | 2023 | Inpefa |
| Cleerly, INC. | $19.67 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stellingworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.